Form 4: Avalo Therapeutics CEO Granted Stock Options
SEC Form 4
Avalo Therapeutics CEO and Chairman, Garry Arthur Neil, was granted 411,000 stock options on January 28, 2025.
Summary
- Garry Arthur Neil, CEO and Chairman of the Board of Avalo Therapeutics, Inc., was granted 411,000 stock options.
- The options have an exercise price of $8.04 per share.
- The options vest 25% on January 28, 2026, with the remaining portion vesting in equal monthly installments over the following three years.
- The vesting is contingent upon Mr. Neil's continued service with the company.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.
Positives
- The granting of stock options aligns the CEO's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Risks
- The value of the stock options is dependent on the future performance of Avalo Therapeutics' stock price.
- If the stock price does not increase above the exercise price, the options will have no value.
Future Outlook
The stock options will vest over the next four years, subject to the CEO's continued service.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard practice for executive compensation in the biotech industry.
- The vesting schedule of 25% after one year and the remainder over three years is fairly typical for such grants.
- Comparable companies in the biotech sector often use similar vesting schedules to incentivize long-term performance.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
- Employees may see this as a sign of stability and commitment from the leadership.
Key Dates
| Date | Description |
|---|---|
| 01/28/2025 | Date of the stock option grant. |
| 01/28/2026 | Date when 25% of the stock options vest. |
| 01/30/2025 | Date of the form filing. |
| 01/28/2035 | Expiration date of the stock options. |
Keywords
stock options, executive compensation, insider trading, Avalo Therapeutics, AVTX, Garry Arthur Neil
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.